Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 22,902 shares at $27.51 ($630K) on 2024-08-26, disclosed to the SEC on 2024-08-28.
Scheduled sale ($630k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.53 | 8,851 | $244K | 38.7% |
| 2 | $27.53 | 8,851 | $244K | 38.7% |
| 3 | $27.51 | 5,200 | $143K | 22.7% |
| Total | $27.53 avg | 22,902 | $630K | 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |